GENB

9.5408.00%
NA

Nancy A. Simonian

Independent Director

Dr. Nancy A. Simonian, M.D., had been a Director of Syros Pharmaceuticals, Inc since April 2013 until February 28, 2025. She had been Chief Executive Officer at Syros Pharmaceuticals, Inc. since July 2012 until December 2, 2023 and served as its President from 2000 until December 2, 2023. Dr. Simonian had been Interim Principal Financial Officer and Principal Accounting Officer of Syros Pharmaceuticals, Inc. since June 16, 2021 until October 2021. She served as the Principal Financial Officer of Syros Pharmaceuticals, Inc. since September 28, 2017 until December 06, 2017. She had been Director at Alltrna, Inc. from Jul, 2024 and is Independent Member of Supervisory Board of Bayer Aktiengesellschaft from April 2024. Dr. Simonian serves as an Independent Director of Generate Biomedicines, Inc. since June 2024. Dr. Simonian served as a Director of Evelo Biosciences, Inc. since April 2018 until 2021. She served as the Chief Medical Officer of Clinical, Medical & Regulatory Affairs at Millennium Pharmaceuticals, Inc. She served as the Chief Medical Officer of Millennium Pharmaceuticals Inc. (now Takeda Pharmaceutical Company) from 2001 to 2011. While at Millennium, Dr. Simonian has built a strong clinical development organization which effectively executes on a diverse pipeline of product candidates in Millennium Pharmaceuticals Inc.'s oncology, inflammatory disease and cardiovascular disease focus areas. She served as Senior Vice President, Clinical, Regulatory and Medical Affairs of Millennium Pharmaceuticals Inc. from March 14, 2005 to 2006. She was Chief Scientific Officer at Millennium Pharmaceuticals, Inc., from 1997 to 2002. She was responsible for guiding the clinical development process for the approval of VELCADE. In her expanded role, Dr. Simonian leads an integrated medical organization which consolidates all medical functions, including clinical development, regulatory affairs, pharmacovigilance and global medical affairs. She joined Millennium Pharmaceuticals in 2001. She co-leads Millennium Pharmaceuticals Inc.’s pipeline portfolio review committee and direct a streamlined clinical drug development process through post-approval life- cycle. Dr. Simonian served at Biogen, Inc. from 1995 to 2001 and also held the positions of Vice President of Medical Research/clinical research. At Biogen, she was responsible for the oversight of Avonex Tysabri, as well as multiple gene therapy clinical development programs. She successfully filed sNDAS for Avonex and led the in-licensing of Tysabri from Elan Pharmaceuticals. She has been a Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since March 2012. She serves as a Director of Syros and the Damon Runyon Cancer Research Foundation. Dr. Simonian served as a Director of Arqule Inc. from May 12, 2006 to March 31, 2011. Dr. Simonian is Assistant Clinical Professor, Neurology, at Harvard Medical School/Massachusetts General Hospital. Dr. Simonian holds a BA in Biology from Princeton University in 1983 and an M.D. from the University Of Pennsylvania Medical School in 1988. Dr. Simonian completed her internship in Medicine and residency in Neurology at Harvard Medical School/Massachusetts General Hospital.

Positions